The safety of curcumin supplementation in CKD patients warrants careful consideration, particularly due to its dose-dependent adverse effects and potential for drug interactions, especially with medications possessing narrow therapeutic windows or those metabolized by CYP enzymes and P-gp. This evidence concerns the gene PPIG and chronic kidney disease.